Glaucoma

The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.

Ophthalmology Times® spoke with Mitch Shultz, MD at ASCRS 2023 in San Diego where he shared insights from his presentation comparing patient results of the Hydrus stent and the iStent inject W with or without ABiC (or ab-interno canaloplasty).

Diagnostic test results may vary in the same patient on the same day.

The iDose TR, a micro-invasive intraocular implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has a PDUFA date of December 22, 2023.

In this recent study, Bharti Nihalani-Gangwani, MD, and Deborah VanderVeen, MD, reported that 29% developed glaucoma in a large infant cohort and the risk factors at the American Society of Cataract and Refractive Surgery annual meeting in San Diego.

Xiongfei Liu, MD, is presenting a talk entitled, "Effectiveness and safety of combining 2 MIGS devices in patients with open angle glaucoma," at ASCRS 2023 in San Diego, California.

Jason Bacharach, MD, presented results at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, highlighting that a large phase 3 clinical trial demonstrated no relevant differences between the 2 formulations.

Inder Paul Singh, MD, sat down with Sheryl Stevenson, Group Editorial Director, Ophthalmology Times®, to discuss his presentation on intraoperative OCT during glaucoma at the ASCRS annual meeting in San Diego.

Eyecelerator kicks off today as the American Society of Cataract and Refractive Surgery will host this year’s ASCRS and ASOA Annual Meeting in San Diego, California, beginning on Friday. ViaLase Inc., Aurion Biotech among companies presenting at the annual meeting.

The medical technology company ViaLase will reveal the 2-year data from their FLigHT clinical study as well as give additional information about their pipeline at ASCRS 2023.

John Samples, MD, shares highlights from his the glaucoma panel discussion during the 2023 Controversies in Modern Eye Care meeting.

I. Paul Singh, MD, gives a brief overview of the glaucoma panel discussion during the 2023 Controversies in Modern Eye Care meeting.

The study found that pseudophakic children older at the time of surgery developed a glaucoma-related adverse event less frequently.

Pediatric glaucoma, although rare, can cause irreversible vision loss and leave children visually impaired if not treated timely and adequately.

Physicians should continue to have conversations and assessments of patients with glaucoma before the decision is reached to stop driving.

A look back on what happened in optometry during the week of March 10-March 16.

Empowering individuals to take greater ownership of their visual health.

This recall is being initiated out of an abundance of caution due to cracks that have developed in some of the units caps of brimonidine tartrate ophthalmic solution bottles

Supplementing vision care with nutrition may protect ocular tissues.

A look back on what's happened in optometry during the week of February 11-February 16.

Medical and surgical technological advances show promise for future glaucoma management.

A look back on what's happened in optometry during the week of February 4-February 9.

According to the Ocular Hypertension Treatment Study, 5 risk factors are associated with high or low risk for primary open-angle glaucoma (POAG), with the intraocular pressure (IOP) historically being the “gold standard” and only modifiable risk factor.

SpyGlass Pharma presented new data at the Glaucoma 360 New Horizons Forum that supports the use of their proprietary drug delivery platform to lower IOP in patients with glaucoma or ocular hypertension.

A look back on what's happened in optometry during the week of Jan. 28-Feb. 2.